1 n 699 subjects from a regional cohort of
466 FGID patients and 233 healthy controls.
2 The era of diagnosing
a FGID only when organic disease has been excluded is wani
3 testing to support a positive diagnosis of
a FGID.
4 n aged 8-17 years who were diagnosed with
an FGID and a primary caretaker independently completed que
5 ent of chronic gastrointestinal symptoms
and FGIDs.
6 d functional gastrointestinal disorders" (
AP-
FGID) has been changed to functional abdominal pain diso
7 This transition between
different FGIDs suggests a common etiopathogenesis.
8 recommendations were generated for
different FGIDs.
9 w insights have been gained in the
different FGIDs in these age groups.
10 overview of the FGIDs field,
differentiates FGIDs from motility and structural disorders, discusses
11 Functional gastrointestinal
disorders (
FGID) are common in the community.
12 Functional gastrointestinal
disorders (
FGID) are defined by a combination of chronic or recurre
13 g the functional gastrointestinal
disorders (
FGID) from a biopsychosocial perspective.
14 with functional gastrointestinal
disorders (
FGID) often experience emotional distress, a perceived l
15 lower functional gastrointestinal
disorders (
FGID).
16 tions in health and functional GI
disorders (
FGID).
17 Functional gastrointestinal
disorders (
FGIDs) are common conditions diagnosed by established sy
18 scent functional gastrointestinal
disorders (
FGIDs) has evolved during the two decade long Rome proce
19 with functional gastrointestinal
disorders (
FGIDs) often experience distress, reduced quality of lif
20 nt of functional gastrointestinal
disorders (
FGIDs), now recognized as disorders of gut-brain interac
21 Functional gastrointestinal
disorders (
FGIDs), the most common diagnoses in gastroenterology ar
22 on of functional gastrointestinal
disorders (
FGIDs).
23 atric functional gastrointestinal
disorders (
FGIDs).
24 f the functional gastrointestinal
disorders (
FGIDs).
25 pathophysiology of functional GI
disorders (
FGIDs).
26 ional gastrointestinal intestinal
disorders (
FGIDs) in infants and toddlers was described.
27 going development of diagnostic criteria
for FGID is therefore warranted.
28 Because of the paucity of data
for FGIDs, we included data for non-gastrointestinal painful
29 s the primary pathophysiologic mechanism
for FGIDs; this opens avenues for newer treatment modalities
30 ors are significantly related to the Rome
II FGID categories of functional oesophageal, bowel and ano
31 ion of various important factors that
impact FGID but are often overlooked.
32 nsideration of important factors that
impact FGIDs, such as gender, age, society, and the patient's p
33 e for sex- and gender-related differences
in FGID, particularly irritable bowel syndrome (IBS).
34 evidence-based review on neuromodulators
in FGID, restricted by the limited available controlled tri
35 The role of the NPS system
in FGID deserves further study.
36 iants are associated with colonic transit
in FGID.
37 iome, diet, and mucosal immune activation
in FGIDs.
38 probabilities were calculated for
individual FGIDs.
39 Rome
IV FGID definitions should enhance clarity for both clinici
40 IBS), functional abdominal pain (FAP),
lower FGID-FD overlap, and high somatic symptom scores.
41 symptom subgroups including IBS, FAP,
lower FGID-FD overlap, or high somatic symptom scores.
42 th different IBS or FAP phenotypes, or
lower FGID-FD overlap.
43 (50.7% CC, 40.8% TC) and patients with
lower FGID (8.6% TT, 51.5% CC, 40.8% TC, and 7.7% TT).
44 rom blood samples of 233 patients with
lower FGID and 152 healthy controls.
45 beta3-C825T genotypes in patients with
lower FGID and healthy controls and to test the associations o
46 There were 159 patients with
lower FGID and overlap FD using Rome II criteria.
47 ciations of the GNbeta3 genotypes with
lower FGID as a group, and subgroups of FGID and somatic sympt
48 ons of GNbeta3-C825T polymorphism with
lower FGID overall or with the separate symptom subgroups incl
49 m is not associated significantly with
lower FGID, with different IBS or FAP phenotypes, or lower FGI
50 rs on the meaning, expression, and course
of FGID are important.
51 n of subjective distress in the diagnosis
of FGID has consequences for actual prevalence rates of FGI
52 ct to ultimately result in the generation
of FGID symptoms.
53 We sought to report the natural history
of FGID in a US population.
54 The natural history
of FGID is unknown because of a lack of prospective populat
55 Whereas the majority
of FGID, including IBS, bloating, constipation, chronic fun
56 significant associations with phenotypes
of FGID symptoms.
57 Prevalence rates
of FGID are high.
58 Prevalence rates
of FGID in our sample were similar to those in other studie
59 consequences for actual prevalence rates
of FGID.
60 38.51% was found in the prevalence rates
of FGID.
61 with lower FGID as a group, and subgroups
of FGID and somatic symptom scores.
62 knowledge about the psychosocial aspects
of FGIDs is fundamental and critical to the understanding,
63 cial pathophysiological conceptualization
of FGIDs, and offers an approach to patient care.
64 ssemination of new knowledge in the field
of FGIDs.
65 Although the majority
of FGIDs, including globus, rumination syndrome, IBS, bloat
66 fairly well established in the management
of FGIDs and benefit from the newer serotonin norepinephrin
67 gender and cross cultural understandings
of FGIDs, 3) reduces the use of imprecise and occassionally
68 ng chronic gastrointestinal pain and
painful FGIDs and serotonin noradrenergic reuptake inhibitors ca
69 Sleep problems are common in
pediatric FGIDs and are associated with functional disability thro
70 and, ultimately, daily function in
pediatric FGIDs.
71 rder patients very likely represent the
same FGIDs that occur in non-ED patients.
72 No difference was seen by
specific FGID or by sex, although adolescents were more likely to
73 and anorectal disorders, and to the
specific FGIDs of IBS, functional abdominal bloating, functional
74 In this web-based
study,
FGID were diagnosed using the Rome II criteria.
75 We also point out
that FGIDs can coexist with other medical conditions that the
76 idated bowel questionnaire characterized
the FGID phenotype: 82 with IBS constipation, 94 with IBS di
77 Although the prevalence of
the FGID was stable over time, the turnover in symptom statu
78 te to the development and maintenance of
the FGID.
79 The FGIDs are a result of complex interactions between biolo
80 ent environmental stress, and several of
the FGIDs but noted that this association is not specific to
81 low and offers an historical overview of
the FGIDs field, differentiates FGIDs from motility and stru
82 ucing symptoms and other consequences of
the FGIDs in children and adults.
83 ted that this association is not specific
to FGIDs.
84 h have been shown to be efficacious to
treat FGID.
85 f exciting new targets to identify and
treat FGIDs and new areas for future research into their patho
86 dence-based review on their use for
treating FGID syndromes.
87 arge sample of children and adolescents
with FGIDs; and, 2) to explore the impact of sleep by examini